CREB1 and nonpapillary renal cell carcinoma: First‐generation CENPE inhibitors (e.g., GSK923295, PF‐2771) have reached phase I with tolerable myelosuppression, and nanomolar CREB1 blockers such as 666‐15—or forthcoming PROTAC degraders—make the CREB1‐CENPE axis pharmacologically tractable in ccRCC.